Hexarelin vs Retatrutide
Well Studied vs Extensively Studied
monitor Mechanism-based · 47% Both Hexarelin and Retatrutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Hexarelin Retatrutide
Weight 887 Da 4,731.33 Da
Half-life 1-2 hours ~6 days
Chain 6 amino acids 39 amino acids
Type Synthetic hexapeptide Triple GLP-1/GIP/glucagon agonist
Key Benefits
Hexarelin
01 Most potent GHRP for GH stimulation
02 Powerful synergy with GHRH peptides
03 Cardioprotective effects via CD36 receptor
04 Enhanced muscle growth and strength
05 Improved fat metabolism
06 Better recovery and tissue repair
07 Maintains natural GH pulsatility
08 Stable against proteolytic enzymes
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Dosing Protocols
Hexarelin
100-200 mcg per injection / 2-3 times daily for optimal GH pulses
GH optimization 100 mcg 2-3x daily
Enhanced results 200 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Cardioprotection 100-200 mcg 1-2x daily
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Side Effects
Hexarelin
Increased appetite (less than GHRP-6)
Water retention
Tingling or numbness
Tiredness after injection
Mild headache
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
WADA prohibited for competitive athletes
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Research Evidence
Hexarelin Retatrutide
Status Well Studied Extensively Studied
References 4 studies 6 studies
Latest — 2025-10
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.